A Michael Coppa, MD
Obstetrics & Gynecology · Cranston, RINPI 1114964251
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,142 with a category attached, or 79.6%. AbbVie accounts for 83.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $2,053 and has fallen 99.0% since, to $21 in 2025.
Across 40 payments — averaging $78.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Bayer$87
- Agile Therapeutics, Inc.$81
- Evofem Biosciences, Inc.$69
- Sumitomo Pharma America, Inc.$53
- Therapeuticsmd, Inc.$51
- plus $193 from 8 others
What the payments were for
- Speaking & faculty fees$2,50080%
- Food & beverage$64220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $2,609 |
| Bayer | 4 | $87 |
| Agile Therapeutics, Inc. | 4 | $81 |
| Evofem Biosciences, Inc. | 4 | $69 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| Therapeuticsmd, Inc. | 3 | $51 |
| Daiichi Sankyo Inc. | 3 | $43 |
| Myovant Sciences Inc. | 2 | $32 |
| Avion Pharmaceuticals | 2 | $26 |
| Coopersurgical, Inc. | 1 | $24 |
| Sage Therapeutics, LLC | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Shield Therapeutics Inc | 1 | $16 |
| Exeltis, USA Inc. | 1 | $12 |
How this compares
$3,142 in reported general payments places this provider in the 80th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremproEstrogen,con/M-Progest Acet | 19 | $4,552 |
| Estradiol (Twice Weekly)Estradiol | 15 | $1,426 |
| ValacyclovirValacyclovir Hcl | 25 | $1,123 |
| Estradiol | 35 | $864 |
| Oxybutynin Chloride | 38 | $838 |
| Alendronate Sodium | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Cranston
- Amr Abdel KaderCranston$2K
- Mary SimpsonWakefield$50K
- Warren HuberProvidence$50K
- Lisa BoyleProvidence$30K
- Renee EgerProvidence$24K
- Mauro ColavitaWarwick$23K
- Gary WhartonProvidence$22K
- Christine FoleyProvidence$21K
- Cara MathewsProvidence$21K
- Michael BeitleProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.